TEM News & Analysis
2 articles
Market Mood
Tempus AI (TEM) Revenue Outlook Boosted by Morgan Stanley Insight
Tempus AI (TEM) shares rose 30% this week after Morgan Stanley highlighted reimbursement pricing that may add between $330 million and $400 million in annual revenue from xT and xF diagnostics. CEO Eric Lefkofsky indicated that xT pricing could contribute $80 million to $100 million next year, while xF could contribute $250 million to $300 million. The company also raised its full-year revenue guidance to between $1.595 billion and $1.605 billion, reflecting approximately 25% annual growth. For investors, the revenue adjustments signify potential growth and a more favorable earnings trajectory moving forward.
Read More: Tempus AI (TEM) Revenue Outlook Boosted by Morgan Stanley Insight
Tempus AI (TEM) Holds $446M Stake by Cathie Wood's Ark Invest
Tempus AI Inc. (NASDAQ:TEM) is ranked #5 in Cathie Wood's AI healthcare stock selections, with a reported stake of $446,275,249. The company focuses on healthcare diagnostics and data aggregation, having amassed over 450 petabytes of clinical and genomic data, enhancing the efficiency of its AI models. Management estimates potential annual revenue exceeding $200 million from expanding into ECG-based testing. This expansion could significantly broaden Tempus' revenue streams, although some investors see other AI stocks as offering greater upside potential.
Read More: Tempus AI (TEM) Holds $446M Stake by Cathie Wood's Ark Invest